Drug class
Fully human monoclonal IgG4 antibody; myostatin-pathway inhibitor
Mechanism of action
Binds promyostatin and latent myostatin and inhibits activation of myostatin, blocking myostatin signalling involved in limiting skeletal-muscle growth.
General use cases
- Treatment of spinal muscular atrophy (SMA) in adults and paediatric patients aged 2 years and older who are currently receiving an SMN2-targeted treatment under the US FDA Isembyld indication (approval 11 Sep 2026)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
